hiccups with semaglutide and Hiccups: What You Need to Know With Even More Powerful GLP-1s

GLP-1 patches dont

Individuals achieving 5% weight loss from baseline body weight had significantly lower AF incidence (OR 0.83, 95% CI 0.780.89), whereas no significant differences were observed in those with no weight loss or weight gain (OR 1.05, 95% CI 0.971.12)

Tirzepatide (Zepbound/Mounjaro): A dual GLP-1/GIP receptor agonist undergoing evaluation for MASH after demonstrating significant liver fat reduction in studies.Retatrutide: A "triple agonist" targeting GLP-1, GIP, and glucagon (GCGR) receptors, which has shown "unprecedented" efficacy in weight loss and is being evaluated for metabolic diseases including MASH

Associated with better metabolic outcomes including weight, glucose, BMI, and blood pressure in clinical trials

Licensed U.S